» Articles » PMID: 38003658

Inflammatory and Metabolic Signaling Interfaces of the Hypertrophic and Senescent Chondrocyte Phenotypes Associated with Osteoarthritis

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Nov 25
PMID 38003658
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoarthritis (OA) is a complex disease of whole joints with progressive cartilage matrix degradation and chondrocyte transformation. The inflammatory features of OA are reflected in increased synovial levels of IL-1β, IL-6 and VEGF, higher levels of TLR-4 binding plasma proteins and increased expression of IL-15, IL-18, IL-10 and Cox2, in cartilage. Chondrocytes in OA undergo hypertrophic and senescent transition; in these states, the expression of Sox-9, Acan and Col2a1 is suppressed, whereas the expression of RunX2, HIF-2α and MMP-13 is significantly increased. NF-kB, which triggers many pro-inflammatory cytokines, works with BMP, Wnt and HIF-2α to link hypertrophy and inflammation. Altered carbohydrate metabolism and the upregulation of GLUT-1 contribute to the formation of end-glycation products that trigger inflammation via the RAGE pathway. In addition, a glycolytic shift, increased rates of oxidative phosphorylation and mitochondrial dysfunction generate reactive oxygen species with deleterious effects. An important surveyor mechanism, the YAP/TAZ signaling system, controls chondrocyte differentiation, inhibits ageing by protecting the nuclear envelope and suppressing NF-kB, MMP-13 and aggrecanases. The inflammatory microenvironment and synthesis of key matrix components are also controlled by SIRT1 and mTORc. Senescent chondrocytes represent the functional end stage of hypertrophic differentiation and characteristically upregulate p16 and p21, but also a variety of inflammatory cytokines, chemokines and metalloproteinases, developing the senescence-associated secretory phenotype. Senolysis with dendrobin, miR29b-5p and other agents has been shown to be efficient under experimental conditions, and appears to be a promising tool for the treatment of OA, as it restores COL2A1 and aggrecan synthesis, suppressing NF-kB and destructive metalloproteinases.

Citing Articles

Pioglitazone Regulates Chondrocyte Metabolism and Attenuates Osteoarthritis by Activating Peroxisome Proliferator-Activated Receptor Gamma.

Shi J, Gong T, Zhou Y J Cell Mol Med. 2025; 29(4):e70456.

PMID: 40008494 PMC: 11862886. DOI: 10.1111/jcmm.70456.


Antioxidant Senotherapy by Natural Compounds: A Beneficial Partner in Cancer Treatment.

Aleksandrova Y, Neganova M Antioxidants (Basel). 2025; 14(2).

PMID: 40002385 PMC: 11851806. DOI: 10.3390/antiox14020199.


Targeting Chondrocyte Hypertrophy as Strategies for the Treatment of Osteoarthritis.

Dong D, Jin G Bioengineering (Basel). 2025; 12(1).

PMID: 39851351 PMC: 11760869. DOI: 10.3390/bioengineering12010077.


Cross-talk of inflammation and cellular senescence: a new insight into the occurrence and progression of osteoarthritis.

Han Z, Wang K, Ding S, Zhang M Bone Res. 2024; 12(1):69.

PMID: 39627227 PMC: 11615234. DOI: 10.1038/s41413-024-00375-z.


Tamarixetin Protects Chondrocytes against IL-1β-Induced Osteoarthritis Phenotype by Inhibiting NF-κB and Activating Nrf2 Signaling.

Lee S, Shin M, Sung J Antioxidants (Basel). 2024; 13(10).

PMID: 39456419 PMC: 11505541. DOI: 10.3390/antiox13101166.


References
1.
Zhang C, Jiang S, Lu Y, Yuan F . Butorphanol tartrate mitigates cellular senescence against tumor necrosis factor -α (TNF-α) in human HC-A chondrocytes. Bioengineered. 2022; 13(3):5434-5442. PMC: 8974103. DOI: 10.1080/21655979.2021.2024651. View

2.
Lu H, Jia C, Wu D, Jin H, Lin Z, Pan J . Fibroblast growth factor 21 (FGF21) alleviates senescence, apoptosis, and extracellular matrix degradation in osteoarthritis via the SIRT1-mTOR signaling pathway. Cell Death Dis. 2021; 12(10):865. PMC: 8460788. DOI: 10.1038/s41419-021-04157-x. View

3.
Rim Y, Nam Y, Ju J . The Role of Chondrocyte Hypertrophy and Senescence in Osteoarthritis Initiation and Progression. Int J Mol Sci. 2020; 21(7). PMC: 7177949. DOI: 10.3390/ijms21072358. View

4.
Nogueira-Recalde U, Lorenzo-Gomez I, Blanco F, Loza M, Grassi D, Shirinsky V . Fibrates as drugs with senolytic and autophagic activity for osteoarthritis therapy. EBioMedicine. 2019; 45:588-605. PMC: 6642320. DOI: 10.1016/j.ebiom.2019.06.049. View

5.
Maneiro E, Martin M, de Andres M, Lopez-Armada M, Fernandez-Sueiro J, del Hoyo P . Mitochondrial respiratory activity is altered in osteoarthritic human articular chondrocytes. Arthritis Rheum. 2003; 48(3):700-8. DOI: 10.1002/art.10837. View